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Background: Hypogonadism is common among HIV-infected men, even among men receiving antiretroviral therapy
(ART). Our objective in this study was to determine the prevalence of biochemical hypogonadism among HIV-infected
men compared with HIV-uninfected controls. We also examined the use of free testosterone (FT) and total testosterone
(TT) measurements in the assessment of biochemical hypogonadism in HIV-infected and –uninfected men.
Methods: This was a cross-sectional analysis from the Multicenter AIDS Cohort Study (MACS). TT levels were measured
from archived serum using liquid chromatography-tandem mass spectrometry. FT was calculated from TT and sex
hormone-binding globulin (SHBG) (measured by radioimmunoassay) using the Vermeulen equation. Biochemical
hypogonadism was defined as having low TT, low FT, or both.
Results: Of 945 men in the MACS Cardiovascular Substudy, T assays were not performed in 89 because of insufficient/
no stored serum (n = 18) or use of T replacement therapy (TRT) (n = 71). 530 men had morning (AM) T measurements;
364 (68.7%) were HIV-infected. The prevalence of biochemical hypogonadism was similar in HIV-infected
(34/364 = 9.3%) and HIV-uninfected (12/166 = 7.2%) men. Prevalence of hypogonadism, when men on TRT (n = 71)
were included in the group of hypogonadal men, was higher in HIV-infected (104/434 = 24.0%) compared with
HIV-uninfected (13/167 = 7.8%) men (p < 0.0001). Of 34 HIV-infected men with biochemical hypogonadism not
on TRT, 11 (32.4%) had normal TT, but low FT. Of 12 HIV-uninfected men with biochemical hypogonadism
not on TRT, none were in this category (p = 0.04) – all had low TT.
Conclusions: The prevalence of biochemical hypogonadism in our sample of HIV-infected men was approximately
10%, with a substantial proportion of these men having a normal TT, but low FT. The measurement of AM FT, rather
than TT, in the assessment of hypogonadism in HIV-infected men will likely increase diagnostic sensitivity and should
be recommended.
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Hypogonadism is common among HIV-infected men,
even among men receiving antiretroviral therapy (ART),
with prevalence estimates ranging from approximately 20%
to 70% [1-3]. The cause of low testosterone (T) in HIV in-
fection is multifactorial, and has been associated with poor
clinical or nutritional status, use of certain prescription/
illicit drugs (including opiates and methadone), pituitary* Correspondence: amonroe4@jhmi.edu
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reproduction in any medium, provided the ordysfunction, HCV co-infection, advancing age, and
changes in body composition [3-5]. Men with clinical
symptoms of hypogonadism, including fatigue, weight
loss, loss of libido or erectile dysfunction, depressive
symptoms, or evidence of reduced bone mineral density,
should undergo a laboratory evaluation for low T.
The Endocrine Society recommends morning (AM)
measurement of total T (TT) as the initial diagnostic test
and subsequent confirmatory test for hypogonadism [6].
Since elevated sex hormone-binding globulin (SHBG)
levels result in higher TT levels, and SHBG is elevated in
HIV-infected men [7,8], the guidelines further recommendl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vated SHBG is suspected [6], including men with HIV. In
addition to having elevated SHBG, HIV-infected men may
have inadequate T production, and as a result of these two
factors, FT (the approximately 2% of T unbound or free to
enter cells to exert metabolic effects) may be below the
lower limit of normal in HIV-infected men even with a
normal TT. Although FT is measured routinely for hypo-
gonadism screening in some HIV clinics [9], the evidence
for this practice has not been well documented. Limited
clinical data has been available to support recommend-
ing FT measurement in HIV-infected men [10], and the
current HIV primary care guidelines currently recommend
measurement of TT for hypogonadism diagnosis [11]. Free
T measurement in HIV-infected men has been recom-
mended by endocrinologists for over ten years [5,12], how-
ever, there may be low uptake of this recommendation
among HIV clinicians, particularly among those who were
not practicing early in the HIV epidemic when hypogonad-
ism in HIV disease was initially described [13].
The objectives of our study were to determine the preva-
lence of hypogonadism among a group of men who par-
ticipate in the Multicenter AIDS Cohort Study (MACS)
and to compare by HIV serostatus biochemical hypo-
gonadism diagnoses made by TT and FT assays.
Methods
This analysis used data collected in the MACS Cardiovas-
cular Disease (CVD) substudy, which has been described
previously [14]. Briefly, the substudy enrolled men older
than 40 years who weighed less than 300 pounds and who
had no history of coronary heart disease. Blood draws were
performed at regularly scheduled MACS follow-up visits
between April 2004 and January 2006. For this analysis, we
included men who had undergone AM blood sampling for
T measurement. Testosterone and SHBG were measured
from archived sera using liquid chromatography-tandem
mass spectrometry and radioimmunoassay, respectively,
and assays were performed in Dr. Shalender Bhasin’s lab at
Boston University. The testosterone assay had a sensitivity
of 2 ng/dL, with an interassay co-efficient of variation ran-
ging from 3.3% to 7.7% with three pooled samples analyzed
in nine different assays. SHBG levels were measured using
a two-site immunofluorometric assay (DELFIA-Wallac,
Inc., Turku, Finland) [15,16]. The inter-assay CVs were
8.3%, 7.9%, and 10.9%, and intra-assay CVs 7.3%, 7.1%
and 8.7%, respectively, in the low, medium, and high pools.
The analytical sensitivity of the assays was 0.5 nmol/L.
The assay has negligible crossreactivity with beta-
microglobulin, thyroxine binding globulin (TBG), or
corticosteroid binding globulin (CBG). Free testosterone
was calculated using the Vermeulen equation [17].
The main outcome variable was biochemical hypogonad-
ism, diagnosed by either FT < 50 pg/mL (< 173.5 pmol/L)or T < 300 ng/dL (< 10.4 nmol/L), consistent with guide-
lines [6]. Wilcoxon rank-sum (Mann–Whitney) and Fisher’s
exact tests were used to compare demographic and clin-
ical characteristics by HIV serostatus. Hormone values were
log-transformed and adjusted by age, clinical site, BMI, and
race. Pearson chi-square tests were used to compare by
HIV serostatus both the prevalence of hypogonadism and
the proportion of men with hypogonadism who had normal
TT and low FT, whose biochemical hypogonadism would
have been missed had only TT been measured.
Results and discusion
Results
The study flow is shown in Figure 1. Of 945 men stud-
ied, T assays were not performed in 89 men, because of
insufficient/no stored serum (n = 18) or because of re-
ceipt of T replacement therapy (TRT) (n = 71). Ninety-
nine percent (70/71) of men excluded for receiving TRT
were HIV-infected. There were 856 men who had a T
assay performed, of whom 326 were excluded because
their blood sample was drawn in the afternoon. Of the
530 men, 364 (68.7%) were HIV-infected and 166 (31.3%)
were HIV-uninfected; Table 1 shows their demographic
and clinical characteristics. The HIV-infected men were
younger, weighed less, and were more likely to have hepa-
titis C virus (HCV) co-infection. Among the HIV-infected
men, median nadir CD4 was 266 cells/mm3 and median
current CD4 was 495 cells/mm3; 32% percent of the men
were not virally suppressed (20.9% were not receiving
ART at the time of the study).
Median TT levels were not significantly different be-
tween HIV-infected and –uninfected men, while median
FT was significantly lower and median SHBG was sig-
nificantly higher in HIV-infected men (Table 1). When
log-transformed hormone values were adjusted for age,
BMI, race (white v. other), clinical site, and HIV serosta-
tus, higher BMI (p < 0.0001) and white race (p = 0.01)
were associated with lower log TT; older age (p < 0.0001)
and HIV-infected serostatus (p = 0.001) were associated
with lower log FT. Higher BMI and white race (p < 0.001
for both) were associated with lower log SHBG while
advancing age (p = 0.01) and HIV-infected serostatus
(p < 0.0001) were associated with higher log SHBG.
The prevalence of biochemical hypogonadism, as de-
fined by either low FT or low T, was similar in HIV-
infected (34/364 = 9.3%) and HIV-uninfected (12/166 =
7.2%) participants (p = 0.42). Prevalence of hypogonadism,
when men on TRT (n = 71) were included in the group of
hypogonadal men, was higher in HIV-infected (104/434 =
24.0%) compared with HIV-uninfected (13/167 = 7.8%)
participants (p < 0.0001). Of the 34 HIV-infected men
with biochemical hypogonadism not on TRT, 11 (32.4%)
had normal T, but low free T. In contrast, of the 12
HIV-uninfected men with biochemical hypogonadism,
Figure 1 Study flow.
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(Figure 2).
Among the 46 men with biochemical hypogondadism,
we compared the proportion with normal TT and low FT
with men who had low TT and either low or normal FT.
Among the HIV-infected hypogonadal men, a full third of







Median Age (years) 51.6 48.1 <0.001
Race – White (%) 68.7 64.3 0.32
Median BMI (kg/m2) 25.8 25.2 0.02
Hepatitis C Virus Positive (%) 7.8 14.6 0.03
Median nadir CD4 cell
count (cells/μL)
— 266 —
Median CD4 cell count
(cells/μL)
— 495 —
HIV RNA ≥ 400 copies/mL — 32% —
Median Total T (ng/dL) 650.4 629.2 0.43
Median Free T (pg/mL) 107.3 100.2 0.005
Median SHBG (nmol/L) 47.3 52.6 0.02TT only had been used for diagnosis, about one-third of
hypogonadal HIV-infected men would have been missed.
In an exploratory analysis of the 34 HIV-infected hypo-
gonadal men, we compared the characteristics of men
who had a normal TT but low FT with men who had a
low TT and low FT. More men with normal TT were
HCV-infected (63.6% versus 11.4%, p = 0.001). Median
[IQR] SHBG was higher among hypogonadal men with
normal T and low FT than hypogonadal men with low T
and low FT (109.0 [81, 143.9] versus 30.2 [20.2, 55.5]
nmol/L, respectively, p < 0.0001). There were no differ-
ences by race, CD4 status, plasma HIV RNA level, or anti-
retroviral therapy status.Figure 2 Proportion of hypogonadal men with normal T, low
FT by HIV status.
Table 2 Proportion of men with biochemical
hypogonadism with normal TT, Low FT by HIV status
HIV-infected HIV-uninfected
Normal TT, Low FT 11/34 (32.3%) 0/12 (0%)
Low TT, Low FT 23/34 (67.6%) 12/12 (100%)
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Among men participating in the MACS CVD substudy
for whom an AM blood sample was available for T assay,
the overall prevalence of biochemical hypogonadism was
8.7% (9.3% among HIV-infected men and 7.2% among
HIV-uninfected men). Prevalence of hypogonadism, when
men on TRT (n = 71) were included in the group of hypo-
gonadal men, was significantly higher in HIV-infected
compared with HIV-uninfected men (24.0% v. 7.8%).
In the men not on TRT, the diagnosis of hypogonad-
ism would have been missed among one-third of HIV
infected men if TT only had been measured, while no
HIV-uninfected men would have gone undiagnosed. Our
results underscore the importance of using free T for
hypogonadism diagnosis among HIV-infected men.
Hypogonadism prevalence among HIV-infected men
has been reported as high as 70% [1-3]. In our cohort,
when including men on TRT, the prevalence of hypo-
gonadism in the HIV-infected men was 24.0%. Preva-
lence varies widely depending on the hypogonadism
definition used and the demographic and clinical charac-
teristics of the cohort, which likely accounts for the dif-
ferences observed between our findings and other groups.
Of note, hypogonadism among HIV-infected men has
remained common despite successful ART [1]. Advancing
age, higher body mass index (BMI) [18] and HCV co-
infection [3] are associated with hypogonadism among
HIV-infected men, and contribute to the persistence of
hypogonadism despite successful ART.
We performed exploratory analyses among the HIV-
infected hypogonadal men, comparing those who had a
normal TT but low FT with men who had a low TT.
Our objective was to evaluate whether we could provide
guidance to clinicians as to which HIV-infected men
would require FT testing; we found that men co-infected
with HCV were more likely to have normal TT but low
FT levels. Hence, HIV/HCV-coinfected men may repre-
sent a population at particular risk for misdiagnosis if TT
alone is used to ascertain the presence of hypogonadism.
Consistent with findings from prior studies [2,7,8] we
found that SHBG levels were higher among HIV-infected
men. The exact pathophysiologic mechanisms accounting
for this finding are unclear. Based on analyses of this same
cohort, we have previously reported that SHBG increases
with increasing age, black race, and HCV infection and
decreases with increasing BMI [8]. Elevations in TT
levels that occur as a result of elevations in SHBGdecrease the diagnostic utility of the TT assay among
HIV-infected men.
There are several limitations to this study. A diagnos-
tic evaluation of hypogonadism is usually initiated be-
cause a patient reports symptoms such as low libido,
fatigue, and low energy. Hypogonadism is a clinical diag-
nosis, and therefore the significance of biochemical
hypogonadism diagnosed by laboratory assays is unclear.
Commercially available testosterone assays vary in qual-
ity, and our assays, performed at a preeminent lab, may
not have generated results that are representative of
those readily available to clinicians using commercial as-
says. It is unclear how well FT calculated by Vermeulen
equation reflects equilibrium dialysis, which is the gold
standard. In our analysis, men with samples drawn after
12 noon were excluded, with an unknown effect on the
outcome. Men receiving T therapy, most of whom were
HIV-infected, were excluded. We presume that these
men were receiving T therapy for diagnosed hypogonad-
ism. By excluding these men, we may have introduced a
selection bias because they may have been diagnosed
using a low TT assay alone, possibly resulting in enrich-
ment of numbers of included men with normal T and
low FT. Even in this scenario, however, the number of
HIV-infected men whose hypogonadism would have
gone undetected by using TT measurement alone would
still have been 11% (rather than the 32.3% we found) if
all of the men who were receiving TRT had both low T
and low free T levels. This represents a rate of hypo-
gonadism still significantly higher than observed among
the HIV-uninfected men. Finally, luteinizing hormone/
follicle stimulating hormone (LH/FSH) levels were not
performed; therefore, we were unable to determine if
hypogonadism was primary or secondary.
The use of TT levels assayed from morning specimens
to diagnose hypogonadism among HIV-infected men
may result in about 30% missed cases. Morning free T
levels are more sensitive diagnostically and should be
measured in all HIV-infected men in whom hypogonad-
ism is suspected.
Conclusions
The prevalence of biochemical hypogonadism in our
overall sample was approximately 10%, and prevalence
of hypogonadism in HIV-infected men, when men on
testosterone therapy were included in the estimate, was
24%. Use of morning TT levels to diagnose hypogonad-
ism in HIV-infected men results in approximately 30%
missed cases. Morning free T levels are more sensitive
diagnostically and should be measured in HIV-infected
men in whom hypogonadism is suspected.
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